Australia's most trusted
source of pharma news
">
Posted 19 March 2026 PM
The FDA has slapped Novo Nordisk with a Warning Letter for unreported semaglutide safety signals, including deaths, with the TGA “considering the issues raised”.
The warning letter relates to a post-marketing adverse drug experience (PADE) inspection conducted at the Plainsboro, New Jersey site in early 2025, which resulted in a Form FDA 483. The FDA issues documents of this nature after an inspection that outlines improper practice or regulatory shortcomings.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.